Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better.
That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) particularly interesting. Both have built powerful businesses, but their advantages come from very different places.
Vertex’s Moat Starts With Disease Dominance
Vertex has spent the better part of two decades building its position in cystic fibrosis, a genetic disease that affects the lungs and other organs. Rather than just treating the symptoms, its drugs are designed to address the underlying genetic problem.
That work has given Vertex Pharmaceuticals Incorporated something difficult for a new competitor to recreate: extensive knowledge of the disease, deep relationships with doctors and patients, and a treatment portfolio that already reaches most eligible patients.
The latest example is ALYFTREK, Vertex’s newer once-daily treatment for cystic fibrosis. It is designed to improve the function of the defective protein responsible for the disease. The drug generated more than $1 billion in revenue during the first half of 2026, and most of that revenue is coming from patients switching from Vertex’s older treatment, TRIKAFTA.
That is an important detail. Vertex isn’t simply trying to defend its market against competitors. It is effectively upgrading its own customer base to a newer product.
And the CF business is now throwing off enough cash to fund Vertex’s next ambitions.
CASGEVY, a gene-editing treatment for certain patients with sickle cell disease and beta thalassemia, is growing rapidly. JOURNAVX, a non-opioid treatment for acute pain, is another new commercial opportunity. Vertex is also building a kidney-disease business and adding rare endocrine diseases through its Crinetics acquisition. Management estimates that two of the acquired drugs could eventually generate about $5 billion in peak annual sales.
The catch is obvious: Vertex now has to prove that its exceptional CF playbook can work outside CF.
Regeneron’s Moat Is More About the Science
Regeneron has taken a different route.
Instead of building its business around one dominant disease franchise, it has spent decades developing an internal research engine capable of producing multiple medicines.
One example is Dupixent, a drug used to treat several inflammatory diseases, including eczema and asthma. Global sales reached $6 billion in the second quarter, up 38% year over year. Regeneron developed the drug with Sanofi, and the two companies have spent nearly two decades working together on its development and commercialization.
Then there is EYLEA HD, a newer version of a treatment for serious eye diseases such as wet age-related macular degeneration. Its U.S. sales reached nearly $600 million in the second quarter, up 52% from a year earlier, and it has now overtaken the original EYLEA in sales.
Libtayo, an immunotherapy used to treat certain cancers, is another growing product.
The bigger point is what sits behind these drugs. Regeneron says its capabilities span genetics, antibody engineering, clinical development, manufacturing, and commercialization. It also has around 50 active clinical programs.
That creates a different kind of moat. The company is not betting that one blockbuster drug will carry the business forever. It is betting that its ability to discover and develop new medicines will repeatedly produce the next generation of blockbusters.
DON’T MISS: 10 Stocks That Will Go to the Moon According to Reddit
The Real Test Comes When Drugs Get Old
Neither strategy is risk-free.
Vertex’s advantage in cystic fibrosis is extraordinarily difficult to challenge, but the company eventually has to diversify beyond it. Its pipeline in kidney disease, pain, blood disorders and endocrine diseases therefore matters enormously.
Regeneron Pharmaceuticals, Inc. has greater diversification, but that does not mean every drug in its pipeline will work. Drug development is inherently uncertain. A company can have an impressive scientific platform and still produce clinical failures.
There is also a warning hiding in Regeneron’s biggest success. Dupixent is approaching a potential U.S. patent expiration later this decade, which means the company cannot simply assume today’s blockbuster revenue will remain protected forever. The company’s expanded collaboration with Sanofi announced this week is partly focused on developing next-generation immunology medicines.
In other words, even the best biotech moats require constant reinvention.
Valuation Changes the Equation
This is where the comparison becomes much more interesting.
At roughly 24.1x forward earnings, Vertex costs about two-thirds more than Regeneron on that basis. Investors are therefore paying a significant premium for Vertex’s unusually strong CF franchise and the possibility that its newer businesses can eventually become meaningful growth engines.
Regeneron, at roughly 14.5x forward earnings, is being valued much more cheaply despite having a collection of successful drugs and a broad development pipeline.
That does not automatically make Regeneron the better investment. A cheap biotech can remain cheap if its best drugs eventually decline and its pipeline fails to replace them.
Likewise, Vertex’s premium can be justified if the company successfully turns its CF expertise and cash generation into several large franchises.
Conclusion
That is what makes these two companies such an interesting comparison. Vertex has built an almost impenetrable moat around one disease and is now trying to replicate that success elsewhere. Regeneron has built something closer to a scientific factory, where the advantage is supposed to come from repeatedly discovering, developing, and commercializing important medicines.
Investors are paying more for Vertex’s moat as the biotech giant seems to have a visible runway due. While it seems more expensive in comparison to Regeneron, its valuation is still relatively reasonable.
READ NEXT: Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack? OR AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up
This article is originally published at Insider Monkey.
Hedge Fund Resource Center